A month after inking a major licensing deal for Ionis Pharmaceuticals, Inc.'s amyloidosis drug eplontersen, AstraZeneca PLC is expanding its efforts in the protein misfolding disorder space by bagging the rights to an early-stage candidate from Swiss biotech Neurimmune Holding AG.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?